All > Diabetic Retinopathy > Macular Degeneration

Stem Cell Therapy

CD34+ bone marrow stem cells intravitreal for Retinitis Pigmentosa

Phase 1

Waitlist Available

Led By Susanna s Park, MD PhD

Research Sponsored by University of California, Davis

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

duration of vision loss > 3 months

the study eye has the worse visual acuity

Must not have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up1 day to 6 months

Awards & highlights

No Placebo-Only Group

Study Summary

This trial is to see if it's safe to inject stem cells from bone marrow into the eye to treat blindness from various retinal conditions.

Eligible Conditions

Retinitis Pigmentosa
Age-Related Macular Degeneration
Retinal Vein Occlusion
Diabetic Retinopathy

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below

Select...

You have experienced vision loss for more than 3 months.

Select...

The eye being studied has worse vision compared to the other eye.

Select...

You do not have any current eye or overall health problems.

Select...

You have been experiencing vision loss for more than three months.

Select...

You do not have any ongoing eye or systemic health problems.

Select...

Your eye with the worst vision will be considered for the study.

Select...

Your eyes do not have any major blockages or cloudiness.

Select...

You do not have any significant vision problems that would make it difficult for doctors to see inside your eyes.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 day to 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 day to 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 day to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence and severity of ocular adverse events

Secondary outcome measures

The number of stem cells isolated and injected into the study eye

Other outcome measures

Incidence and severity of systemic adverse events

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Stem cell treatedExperimental Treatment1 Intervention

0 / 8Eligibility criteria met

Find a site

Who is running the clinical trial?

University of California, DavisLead Sponsor

884 Previous Clinical Trials

5,027,321 Total Patients Enrolled

2 Trials studying Retinitis Pigmentosa

442 Patients Enrolled for Retinitis Pigmentosa

Susanna s Park, MD PhDPrincipal Investigator

University of California Davis Eye Center

Media Library

CD34+ bone marrow stem cells (Stem Cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT01736059 — Phase 1

Retinitis Pigmentosa Research Study Groups: Stem cell treated

Retinitis Pigmentosa Clinical Trial 2023: CD34+ bone marrow stem cells Highlights & Side Effects. Trial Name: NCT01736059 — Phase 1

CD34+ bone marrow stem cells (Stem Cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01736059 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this study's eligibility criteria restrict those aged eighteen or older?

"This medical trial will include patients that are at least 18 years old and not older than 100."

Answered by AI

Is there an opportunity for me to participate in this experiment?

"Eligibility criteria for this clinical trial necessitates that potential participants possess retinitis pigmentosa and be between 18 to 100 years of age. Approximately 15 candidates will be selected in total."

Answered by AI

Are there any federal regulations for intravitreal injections of CD34+ bone marrow stem cells?

"Owing to the limited clinical data surrounding CD34+ bone marrow stem cells intravitreal, it was assigned a score of 1 on our safety scale. This assessment is reflective of its Phase 1 status."

Answered by AI

Is this research study recruiting participants at this time?

"The data from clinicaltrials.gov shows that this particular trial, which was originally added on July 1st 2012 and last updated on August 8th 2022, is no longer accepting candidates. Fortunately, there are 299 other trials in need of participants currently available."

Answered by AI